Renal Cancer
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival.
January 25, 2021
Dana-Farber Research Supports FDA Approval for Combination of Nivolumab and Cabozantinib in Advanced Kidney Cancer
January 23, 2021
Cabozantinib Receives U.S. FDA Approval as a First-Line Treatment in Combination with Nivolumab for Advanced Renal Cell Carcinoma
January 22, 2021
Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC).
January 22, 2021
Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis.
January 22, 2021
CircPVT1 promotes progression in clear cell renal cell carcinoma by sponging miR-145-5p and regulating TBX15 expression.
January 20, 2021
Deep learning based prediction of prognosis in nonmetastatic clear cell renal cell carcinoma.
January 20, 2021
Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma.
January 19, 2021
Available active surveillance follow-up protocols for small renal mass: a systematic review.
January 18, 2021
Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience.
January 15, 2021
Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma.
January 15, 2021